JTT-130 suppresses high-fat diet-induced obesity and improves glucose and lipid metabolic abnormalities with the elevation of plasma glucagon-like peptide-1 (GLP-1) levels in SD rats and Zucker diabetic fatty rats [11–13]. This evidence concerns the gene GCG and obesity disorder.